{
    "clinical_study": {
        "@rank": "43724", 
        "acronym": "PROTECT-1", 
        "arm_group": [
            {
                "arm_group_label": "LT-02", 
                "arm_group_type": "Experimental", 
                "description": "LT-02 0.8g four times daily"
            }, 
            {
                "arm_group_label": "B: LT-02", 
                "arm_group_type": "Experimental", 
                "description": "LT-02 1.6g twice daily"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "LT-02 Placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to compare two different dosing regimens of phosphatidylcholine\n      versus placebo for the induction of remission in ulcerative colitis patients non-responsive\n      to standard mesalamine treatment."
        }, 
        "brief_title": "Phosphatidylcholine (LT-02) for Induction of Remission in Ulcerative Colitis", 
        "completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Ulcerative Colitis", 
        "condition_browse": {
            "mesh_term": [
                "Colitis", 
                "Colitis, Ulcerative", 
                "Ulcer"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Established diagnosis of ulcerative colitis\n\n          -  Active ulcerative colitis disease extent \u2265 15 cm\n\n          -  Active disease despite treatment with mesalamine\n\n        Exclusion Criteria:\n\n          -  Crohn's disease, indeterminate colitis, ischemic colitis, radiation colitis,\n             microscopic colitis, diverticular disease associated colitis,\n\n          -  Toxic megacolon or fulminant colitis\n\n          -  Colon resection\n\n          -  Evidence of infectious colitis\n\n          -  Celiac disease\n\n          -  Bleeding hemorrhoids\n\n          -  History or presence of ischemic heart disease, myocardial infarction, peripheral\n             arterial disease, ischemic stroke, or transient ischemic attack\n\n          -  Any severe concomitant renal, endocrine, or psychiatric disorder\n\n          -  Any relevant known systemic disease\n\n          -  History of cancer in the last five years\n\n          -  Abnormal hepatic function or liver cirrhosis\n\n          -  Abnormal HbA1c at screening visit\n\n          -  Patients with known hypersensitivity to soy\n\n          -  Known intolerance/hypersensitivity to Investigational Medicinal Product (IMP)\n\n          -  Treatment with steroids/methotrexate/Tumor necrosis\n             factor-alpha-antagonists/azathioprine/ 6-mercaptopurine/anti-integrin/coumarins\n\n          -  Treatment with other investigational drug\n\n          -  Existing or intended pregnancy or breast-feeding"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "762", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 15, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02142725", 
            "org_study_id": "PCG-2/UCA", 
            "secondary_id": "2012-003702-27"
        }, 
        "intervention": [
            {
                "arm_group_label": "LT-02", 
                "description": "four times per day", 
                "intervention_name": "LT-02", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "B: LT-02", 
                "description": "two times per day", 
                "intervention_name": "LT-02", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "four times per day", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 19, 2014", 
        "location": {
            "contact": {
                "email": "axel.dignass@fdk.info", 
                "last_name": "Axel Dignass, MD", 
                "phone": "+49-69-9533", 
                "phone_ext": "2201"
            }, 
            "facility": {
                "address": {
                    "city": "Frankfurt a.M.", 
                    "country": "Germany", 
                    "zip": "60431"
                }, 
                "name": "Agaplesion Markus-Krankenhaus, 1st Dept. of Medicine"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "3", 
        "official_title": "Randomized, Double-blind, Double-dummy, Placebo-controlled, Phase III Clinical Trial on the Efficacy and Safety of a 12-weeks add-on Treatment With LT 02 vs. Placebo in Patients With Ulcerative Colitis Refractory to Standard Treatment With Mesalamine", 
        "overall_contact": {
            "email": "mueller@drfalkpharma.de", 
            "last_name": "Ralph M\u00fcller, PhD", 
            "phone": "+49-761-1514", 
            "phone_ext": "101"
        }, 
        "overall_contact_backup": {
            "email": "greinwald@drfalkpharma.de", 
            "last_name": "Roland Greinwald, PhD", 
            "phone": "+49 761 1514", 
            "phone_ext": "0"
        }, 
        "overall_official": {
            "affiliation": "Agaplesion Markus-Krankenhaus, 1st Dept. of Medicine", 
            "last_name": "Axel Dignass, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "September 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Rate of clinical remission", 
            "safety_issue": "No", 
            "time_frame": "12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02142725"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Rate of patients with clinical improvement", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "Time to first resolution of symptoms", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "Number of stools per week", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "Number of days with urgency per week", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "Rate of mucosal healing", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "Rate of histologic remission", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "Physician's global assessment at final visit", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "Quality of life", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }
        ], 
        "source": "Dr. Falk Pharma GmbH", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Dr. Falk Pharma GmbH", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}